TroVax (5T4 cancer vaccine)

09/01/2006 - "In a pre-clinical murine model, the recombinant virus (TroVax) induces protection against challenge with CT26-h5T4 (a syngeneic tumor line expressing h5T4). "
10/01/2002 - "In active treatment studies, inoculation with MVA-h5T4 was able to treat established CT26-h5T4 lung tumor and to a lesser extent B16.h5T4 s.c. "
09/01/2006 - "In a therapeutic setting, injection of mice with TroVax results in a reduction in tumor burden of >90%. "
01/01/2012 - "This article will discuss the clinical background of RCC, the rationale for TroVax development, results of several TroVax clinical trials and future directions for optimizing TroVax therapy in patients with RCC and other cancers."
10/01/2002 - "C57BL/6 and BALB/c mice vaccinated with MVA-h5T4 were challenged with syngeneic tumor line transfectants, B16 melanoma, and CT26 colorectal cells that express h5T4. "

06/01/2011 - "Patients with renal cancer and requiring first-line treatment for metastatic disease were randomized 1:1 to receive MVA-5T4 (TroVax(®)) or placebo alongside Sunitinib, IL-2 or IFN-α in a multicentre phase III trial. "
05/01/2009 - "Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha."

05/01/2009 - "The attenuated strain of vaccinia virus, modified vaccinia Ankara, has been engineered to express 5T4 (TroVax). "
09/01/2009 - "Attenuated vaccinia virus, modified vaccinia Ankara (MVA) has been engineered to deliver the tumor antigen 5T4 (TroVax). "
11/15/2008 - "The attenuated vaccinia virus modified vaccinia ankara (MVA) has been engineered to deliver the tumor antigen 5T4 (TroVax). "
07/01/2008 - "The attenuated vaccinia virus, modified vaccinia Ankara, has been engineered to deliver the tumor antigen 5T4 (TroVax). "
07/01/2008 - "Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial."

01/01/2014 - "TroVax in colorectal cancer."
07/01/2008 - "TroVax was administered to 19 patients with metastatic colorectal cancer. "
08/01/2007 - "TroVax was administered to 17 patients with metastatic colorectal cancer. "
06/01/2006 - "TroVax was given to 22 patients with metastatic colorectal cancer. "
10/01/2009 - "Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4)."

01/01/2012 - "TroVax(®) vaccine therapy for renal cell carcinoma."
05/01/2009 - "We conducted an open-label phase 1/2 trial in which TroVax was administered alongside interferon-alpha (IFNalpha) to 11 patients with metastatic renal cell carcinoma. "
06/01/2008 - "Its restricted expression on tumour tissues as well as its association with tumour progression and bad prognosis has driven the development of a MVA-based vaccine (TroVax) which has been tested in several early phase clinical trials and these studies have led to the start of a phase III trial in renal cell carcinoma patients. "
11/15/2008 - "Twenty-five patients with metastatic renal cell cancer were treated with TroVax plus IL-2. "
11/15/2008 - "TroVax has been evaluated in an open-label phase II trial in metastatic renal cell cancer patients in which the vaccine was administered in combination with interleukin-2 (IL-2). "